McKesson stock raises fiscal 2027 adjusted EPS outlook

McKesson reported stronger fiscal second-quarter results on November 4, 2026, and raised its adjusted earnings outlook for fiscal 2027. In its earnings release, the company said revenue increased 8% year over year to 111.0 billion US dollars for the quarter ended September 30.

McKesson stock traded at 956.10 euros on Lang & Schwarz at 13:34 CET on Tuesday, November 10. No verified Xetra closing price was available for a same-day comparison, so the quote is presented without a directional percentage change.

Quarterly growth broadens across segments

Reported diluted earnings per share rose to 10.44 US dollars from 8.92 US dollars a year earlier. Adjusted earnings per diluted share increased 18% to 11.68 US dollars from 9.86 US dollars. McKesson attributed the adjusted improvement to operating growth in North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions, as well as a lower share count.

North American Pharmaceutical revenue rose 6% to 91.4 billion US dollars, while adjusted segment operating profit increased 22% to 1.0 billion US dollars. Oncology & Multispecialty revenue gained 24% to 15.0 billion US dollars, with adjusted segment operating profit up 8% to 427 million US dollars.

Prescription Technology Solutions revenue increased 10% to 1.5 billion US dollars and adjusted segment operating profit rose 18% to 307 million US dollars. Medical-Surgical Solutions revenue grew 5% to 3.1 billion US dollars, but adjusted segment operating profit fell 10% to 225 million US dollars because of product mix in the ambulatory care channel.

Higher guidance sets the next benchmark

McKesson lifted its fiscal 2027 adjusted earnings per diluted share range to 45.60 to 46.40 US dollars from 44.20 to 45.00 US dollars. The updated range implies growth of 17% to 19% compared with the prior fiscal year. The company does not provide forward-looking GAAP earnings guidance because it cannot reasonably quantify several adjustments, including LIFO inventory effects, litigation items and transaction-related costs.

Chief Executive Officer Brian Tyler described the quarter as another period of operational strength and said the company was continuing to invest in healthcare capabilities. Chief Financial Officer Kenny Cheung said the higher outlook reflected business strength and confidence in consistent execution.

McKesson generated 3.1 billion US dollars of operating cash flow and 2.9 billion US dollars of free cash flow in the quarter. In the first six months of the fiscal year, it returned 3.6 billion US dollars to shareholders through 3.4 billion US dollars of common-stock repurchases and 198 million US dollars of dividends.

Portfolio expansion adds strategic focus

The company completed its acquisition of Precision Medicine Group on November 2, 2026. McKesson said the transaction strengthens its position in oncology, multispecialty care and biopharma services. It also signed an agreement to invest approximately 1.4 billion US dollars for a minority stake of approximately 49% in Option Care Health, subject to shareholder and regulatory approvals.

Management is scheduled to participate in the Jefferies Global Healthcare Conference on November 17, followed by events in December and January. For investors, execution against the raised profit range and the integration of recent strategic moves are the next principal markers for the shares.

US equity markets provide the broader backdrop for investors in McKesson stock, as reflected by the S&P 500.

Broader developments are available in Current market reports, alongside More news and analyses on McKesson stock.

McKesson Corporation

• ISIN: US58155Q1031
• Ticker: MCK
• Home exchange: NYSE
• Lang & Schwarz price: 956.10 euros on November 10, 2026, at 13:34 CET